Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs BI 655130 (Primary) ; BI 655130 (Primary)
- Indications Pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Nov 2017 Planned End Date changed from 16 Dec 2017 to 5 Jan 2018.
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 30 May 2017 Status changed from not yet recruiting to recruiting.